Frederick S. Hagen

Dr. Frederick S. Hagen is founder, President, and CEO of Icogenex. During his tenure at ZymoGenetics, from 1982 to 1994, Dr. Hagen served in a number of leadership roles. Major accomplishments include cloning and expression of the cDNA for Factor VII. This blood coagulation protein is currently over a $1 billion a year product for Novo Nordisk. Another discovery was the identification of cDNA encoding Thrombopoietin, the growth factor regulator of platelet production that was licensed to Amgen.

In 13 years with ZymoGenetics, Dr. Hagen experienced first-hand the development and maturation of a biotechnology company from startup through buyout by Novo Nordisk. While at ZymoGenetics, he also worked for a year at Novo Nordisk headquarters in Copenhagen, Denmark, where he gained experience in the operations of a large pharmaceutical company.

Dr. Hagen has 21 issued patents and is an author on 34 peer-reviewed journal articles. Dr Hagen received his Ph.D. from the University of Washington and completed his postdoctoral work at Harvard Medical School.